Amicus Therapeutics
FOLD · NASDAQ
Bulios Fair Price
$10.19
29.7% downside
Current Price
$14.49
According to Bulios Fair Price, FOLD is currently overvalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
About the company
Amicus Therapeutics, Inc. is an American biotechnology company specializing in the development of innovative therapies for the treatment of rare genetic diseases, particularly lysosomal storage disorders. The company focuses on developing enzyme replacement therapies and other biologic treatments that can improve the health of patients suffering from diseases such as Fabry disease, Gaucher disease, and Pompe disease. Amicus Therapeutics is known for its advanced research in enzyme therapy and highly targeted treatment methods, offering new possibilities for patients for whom current treatments have been insufficiently effective.
Sector
Healthcare
Industry
Biotechnology
CEO
Bradley L. Campbell
Employees
499
Headquarters
Philadelphia